At the end of this session the participants will be able to:
- Identify the novel AEDs in preclinical and clinical trials.
- Describe the potency and efficacy of the novel AEDs in animal seizure models.
- Describe the clinical studies done in healthy volunteers and epileptic patients with the novel AEDs.
- Gain an insight into the toxicological, pharmacokinetic and mechanistic studies of the novel AEDs in development.
In the last two decades sixteen new antiepileptic drugs (AEDs) have been introduced to the market. Compared to the late 1960s the number of patients with refractory epilepsy has not been significantly reduced. In addition to efficacy current pharmacotherapy suffers from adverse effect and drug-drug interactions. This enables the development of novel more efficacious and better tolerated AEDs. The presentation will cover the novel antiepileptic drugs currently in different developmental stages in preclinical and clinical trials. The following novel drugs will be discussed: brivaracetam, 2-deoxy-glucose, ganaxolone, ICA-105665, imepitoin, NAX 801-2, perampanel, tonabersat, sec-propylbutylacetamide (SPD), VX-765. This presentation will also provide a status update on the clinical studies in both healthy volunteers and epilepsy patients with an emphasis on tolerability, pharmacokinetics and side effect profile.